{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T14:24:18Z","timestamp":1790605458938,"version":"4.1.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The use of medical\n                    <jats:italic>Cannabis<\/jats:italic>\n                    has increased in recent years due to changing legal circumstances in many countries. Approval exists only for a few neurological conditions such as rare forms of epilepsy or spasticity in multiple sclerosis. Beyond that, however, medical Cannabis is used for a wide range of neurological conditions and symptoms. In Germany, in parallel with new legislation that has simplified the prescription of medical\n                    <jats:italic>Cannabis<\/jats:italic>\n                    , an accompanying survey has been implemented for which initial data are now available. In this context, our review provides an overview of the evidence for the therapeutic use of medical\n                    <jats:italic>Cannabis<\/jats:italic>\n                    in neurology, the potential benefits, and side effects.\n                  <\/jats:p>","DOI":"10.1007\/s00702-023-02719-1","type":"journal-article","created":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T10:02:39Z","timestamp":1701165759000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Therapeutic use of medical Cannabis in neurological diseases: a clinical update"],"prefix":"10.1007","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-1821","authenticated-orcid":false,"given":"Ute","family":"Hidding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0597-2648","authenticated-orcid":false,"given":"Tina","family":"Mainka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-3789","authenticated-orcid":false,"given":"Carsten","family":"Buhmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"2719_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CLINEURO.2020.105990","volume":"196","author":"G Alessandria","year":"2020","unstructured":"Alessandria G, Meli R, Infante MT et al (2020) Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: a pilot study. Clin Neurol Neurosurg 196:105990. https:\/\/doi.org\/10.1016\/J.CLINEURO.2020.105990","journal-title":"Clin Neurol Neurosurg"},{"key":"2719_CR2","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.28577","volume":"36","author":"CMO Almeida","year":"2021","unstructured":"Almeida CMO, Brito MMC, Bosaipo NB et al (2021) Cannabidiol for rapid eye movement sleep behavior disorder. Mov Disord 36:1711\u20131715. https:\/\/doi.org\/10.1002\/mds.28577","journal-title":"Mov Disord"},{"key":"2719_CR3","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5141773","author":"S Anis","year":"2022","unstructured":"Anis S, Zalomek C, Korczyn AD et al (2022) Medical Cannabis for Gilles de la Tourette Syndrome: an open-label prospective study. Behav Neurol. https:\/\/doi.org\/10.1155\/2022\/5141773","journal-title":"Behav Neurol"},{"key":"2719_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40263-019-00627-1","volume":"33","author":"BB Artukoglu","year":"2019","unstructured":"Artukoglu BB, Bloch MH (2019) The potential of Cannabinoid-based treatments in Tourette syndrome. CNS Drugs 33:417\u2013430. https:\/\/doi.org\/10.1007\/s40263-019-00627-1","journal-title":"CNS Drugs"},{"key":"2719_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/CAN.2021.0187","volume":"8","author":"V Belgers","year":"2023","unstructured":"Belgers V, R\u00f6ttgering JG, Douw L et al (2023) Cannabinoids to improve health-related quality of life in patients with neurological or oncological disease: a meta-analysis. Cannabis Cannabinoid Res 8:41\u201355. https:\/\/doi.org\/10.1089\/CAN.2021.0187","journal-title":"Cannabis Cannabinoid Res"},{"key":"2719_CR6","unstructured":"BfArM (2022a) Abschlussbericht der Begleiterhebung nach \u00a7 31 Absatz 6 des F\u00fcnften Buches Sozialgesetzbuch zur Verschreibung und Anwendung von Cannabisarzneimitteln"},{"key":"2719_CR7","unstructured":"BfArM (2022b) Anhang 1 zum Abschlussbericht: Erg\u00e4nzende Informationen zu den Fragen 1 bis 14 der Begleiterhebung"},{"key":"2719_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.989717","volume":"13","author":"S Bhunia","year":"2022","unstructured":"Bhunia S, Kolishetti N, Arias AY et al (2022) Cannabidiol for neurodegenerative disorders: a comprehensive review. Front Pharmacol 13:989717. https:\/\/doi.org\/10.3389\/fphar.2022.989717","journal-title":"Front Pharmacol"},{"key":"2719_CR9","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/EJP.1957","volume":"26","author":"P Bialas","year":"2022","unstructured":"Bialas P, Fitzcharles MA, Klose P, H\u00e4user W (2022) Long-term observational studies with cannabis-based medicines for chronic non-cancer pain: a systematic review and meta-analysis of effectiveness and safety. Eur J Pain (united Kingdom) 26:1221\u20131233. https:\/\/doi.org\/10.1002\/EJP.1957","journal-title":"Eur J Pain (united Kingdom)"},{"key":"2719_CR10","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G et al (2019) Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry 6:995\u20131010. https:\/\/doi.org\/10.1016\/S2215-0366(19)30401-8","journal-title":"Lancet Psychiatry"},{"key":"2719_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/FPSYT.2021.596601\/BIBTEX","volume":"12","author":"J Bourque","year":"2021","unstructured":"Bourque J, Potvin S (2021) Cannabis and cognitive functioning: from acute to residual effects, from randomized controlled trials to prospective designs. Front Psychiatry 12:596601. https:\/\/doi.org\/10.3389\/FPSYT.2021.596601\/BIBTEX","journal-title":"Front Psychiatry"},{"key":"2719_CR12","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1590\/0004-282x-anp-2020-0432","volume":"79","author":"SMD Brucki","year":"2021","unstructured":"Brucki SMD, Adoni T, Almeida CMO et al (2021) Cannabinoids in neurology\u2014position paper from scientific departments from Brazilian Academy of Neurology. Arq Neuropsiquiatr 79:354\u2013369. https:\/\/doi.org\/10.1590\/0004-282x-anp-2020-0432","journal-title":"Arq Neuropsiquiatr"},{"key":"2719_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1055\/s-0033-1349884","volume":"40","author":"C Buhmann","year":"2013","unstructured":"Buhmann C, Gerloff C (2013) Autofahren Bei Morbus Parkinson. Aktuelle Neurologie 40:315\u2013320. https:\/\/doi.org\/10.1055\/s-0033-1349884","journal-title":"Aktuelle Neurologie"},{"key":"2719_CR14","unstructured":"Bundestag D (2017) Deutscher Bundestag. Gesetz zur \u00c4nderung bet\u00e4ubungsmittel-rechtlicher und anderer Vorschriften (06. M\u00e4rz 2017)"},{"key":"2719_CR15","unstructured":"Kassen\u00e4rztliche Bundesvereinigung (2023) Arzneimittel-Verordnung. Cannabis\u2014was \u00c4rzte bei der Verordnung wissen m\u00fcssen"},{"key":"2719_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1080\/14737175.2022.2075263","volume":"22","author":"FJ Carod-Artal","year":"2022","unstructured":"Carod-Artal FJ, Adjamian P, Vila Silv\u00e1n C et al (2022) A systematic review of European regional and national guidelines: a focus on the recommended use of nabiximols in the management of spasticity in multiple sclerosis. Expert Rev Neurother 22:499\u2013511. https:\/\/doi.org\/10.1080\/14737175.2022.2075263","journal-title":"Expert Rev Neurother"},{"key":"2719_CR17","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.WNL.0000140288.48796.8E","volume":"63","author":"CB Carroll","year":"2004","unstructured":"Carroll CB, Bain PG, Teare L et al (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245\u20131250. https:\/\/doi.org\/10.1212\/01.WNL.0000140288.48796.8E","journal-title":"Neurology"},{"key":"2719_CR18","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088\u20131098. https:\/\/doi.org\/10.1177\/0269881114550355","journal-title":"J Psychopharmacol"},{"key":"2719_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3109\/00207458608985678","volume":"30","author":"P Consroe","year":"1986","unstructured":"Consroe P, Sandyk R, Snider SR (1986) Open label evaluation of cannabidiol in dystonic movement disorders. Int J Neurosci 30:277\u2013282. https:\/\/doi.org\/10.3109\/00207458608985678","journal-title":"Int J Neurosci"},{"key":"2719_CR20","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/0091-3057(91)90386-G","volume":"40","author":"P Consroe","year":"1991","unstructured":"Consroe P, Laguna J, Allender J et al (1991) Controlled clinical trial of cannabidiol in Huntington\u2019s disease. Pharmacol Biochem Behav 40:701\u2013708. https:\/\/doi.org\/10.1016\/0091-3057(91)90386-G","journal-title":"Pharmacol Biochem Behav"},{"key":"2719_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117206","volume":"419","author":"B Cravanas","year":"2020","unstructured":"Cravanas B, Frei K (2020) The effects of Cannabis on hallucinations in Parkinson\u2019s disease patients. J Neurol Sci 419:117206. https:\/\/doi.org\/10.1016\/j.jns.2020.117206","journal-title":"J Neurol Sci"},{"key":"2719_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","volume":"16","author":"L Cristino","year":"2020","unstructured":"Cristino L, Bisogno T, Di Marzo V (2020) Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol 16:9\u201329. https:\/\/doi.org\/10.1038\/s41582-019-0284-z","journal-title":"Nat Rev Neurol"},{"key":"2719_CR23","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1002\/MDS.22809","volume":"24","author":"A Curtis","year":"2009","unstructured":"Curtis A, Mitchell I, Patel S et al (2009) A pilot study using nabilone for symptomatic treatment in Huntington\u2019s disease. Mov Disord 24:2254\u20132259. https:\/\/doi.org\/10.1002\/MDS.22809","journal-title":"Mov Disord"},{"key":"2719_CR24","doi-asserted-by":"publisher","DOI":"10.1089\/CAN.2021.0158","author":"CMO de Almeida","year":"2023","unstructured":"de Almeida CMO, Brito MMC, Bosaipo NB et al (2023) The Effect of Cannabidiol for Restless Legs Syndrome\/Willis-Ekbom Disease in Parkinson\u2019s Disease Patients with REM Sleep Behavior Disorder: a Post Hoc Exploratory Analysis of Phase 2\/3 Clinical Trial. Cannabis Cannabinoid Res. https:\/\/doi.org\/10.1089\/CAN.2021.0158","journal-title":"Cannabis Cannabinoid Res"},{"key":"2719_CR25","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L et al (2017) Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med 376:2011\u20132020. https:\/\/doi.org\/10.1056\/NEJMoa1611618","journal-title":"N Engl J Med"},{"key":"2719_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/epi.14608","volume":"60","author":"J Elliott","year":"2019","unstructured":"Elliott J, DeJean D, Clifford T et al (2019) Cannabis-based products for pediatric epilepsy: a systematic review. Epilepsia 60:6\u201319. https:\/\/doi.org\/10.1111\/epi.14608","journal-title":"Epilepsia"},{"key":"2719_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ane.13602","volume":"145","author":"AH Erga","year":"2022","unstructured":"Erga AH, Maple-Gr\u00f8dem J, Alves G (2022) Cannabis use in Parkinson\u2019s disease\u2014a nationwide online survey study. Acta Neurol Scand 145:692\u2013697. https:\/\/doi.org\/10.1111\/ane.13602","journal-title":"Acta Neurol Scand"},{"key":"2719_CR28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41531-021-00165-y","volume":"7","author":"MP Feeney","year":"2021","unstructured":"Feeney MP, Bega D, Kluger BM et al (2021) Weeding through the haze: a survey on cannabis use among people living with Parkinson\u2019s disease in the US. NPJ Parkinsons Dis 7:21. https:\/\/doi.org\/10.1038\/s41531-021-00165-y","journal-title":"NPJ Parkinsons Dis"},{"key":"2719_CR29","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1212\/CPJ.0000000000000162","volume":"5","author":"TD Fife","year":"2015","unstructured":"Fife TD, Moawad H, Moschonas C et al (2015) Clinical perspectives on medical marijuana (cannabis) for neurologic disorders. Neurol Clin Pract 5:344\u2013351. https:\/\/doi.org\/10.1212\/CPJ.0000000000000162","journal-title":"Neurol Clin Pract"},{"key":"2719_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013444.PUB2\/MEDIA\/CDSR\/CD013444\/IMAGE_N\/NCD013444-CMP-001.19.SVG","author":"G Filippini","year":"2022","unstructured":"Filippini G, Minozzi S, Borrelli F et al (2022) Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD013444.PUB2\/MEDIA\/CDSR\/CD013444\/IMAGE_N\/NCD013444-CMP-001.19.SVG","journal-title":"Cochrane Database Syst Rev"},{"key":"2719_CR31","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/J.PAIN.0000000000001929","volume":"162","author":"E Fisher","year":"2021","unstructured":"Fisher E, Moore RA, Fogarty AE et al (2021) Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 162:S45\u2013S66. https:\/\/doi.org\/10.1097\/J.PAIN.0000000000001929","journal-title":"Pain"},{"key":"2719_CR32","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/MDS.1280","volume":"17","author":"SH Fox","year":"2002","unstructured":"Fox SH, Kellett M, Moore AP et al (2002) Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Mov Disord 17:145\u2013149. https:\/\/doi.org\/10.1002\/MDS.1280","journal-title":"Mov Disord"},{"key":"2719_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/jnnp.53.5.436","volume":"53","author":"JP Frankel","year":"1990","unstructured":"Frankel JP, Hughes A, Lees AJ, Stern GM (1990) Marijuana for parkinsonian tremor. J Neurol Neurosurg Psychiatry 53:436. https:\/\/doi.org\/10.1136\/jnnp.53.5.436","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2719_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ANE.12287","volume":"131","author":"M Freidel","year":"2015","unstructured":"Freidel M, Tiel-Wilck K, Schreiber H et al (2015) Drug-resistant MS spasticity treatment with Sativex(\u00ae) add-on and driving ability. Acta Neurol Scand 131:9\u201316. https:\/\/doi.org\/10.1111\/ANE.12287","journal-title":"Acta Neurol Scand"},{"key":"2719_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3390\/medicines5030091","volume":"5","author":"F Gado","year":"2018","unstructured":"Gado F, Digiacomo M, Macchia M et al (2018) Traditional Uses of Cannabinoids and New Perspectives in the Treatment of Multiple Sclerosis. Medicines 5:91. https:\/\/doi.org\/10.3390\/medicines5030091","journal-title":"Medicines"},{"key":"2719_CR36","first-page":"45","volume":"25","author":"B Gauter","year":"2004","unstructured":"Gauter B, Rukwied R, Konrad C (2004) Cannabinoid agonists in the treatment of blepharospasm\u2013a case report study. Neuro Endocrinol Lett 25:45\u201348","journal-title":"Neuro Endocrinol Lett"},{"key":"2719_CR37","unstructured":"Grotenhermen F, H\u00e4u\u00dfermann K (2017) Cannabis Verordnungshilfe f\u00fcr \u00c4rzte"},{"key":"2719_CR38","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/J.PAIN.0000000000002266","volume":"162","author":"S Haroutounian","year":"2021","unstructured":"Haroutounian S, Arendt-Nielsen L, Belton J et al (2021) International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain 162:S117\u2013S124. https:\/\/doi.org\/10.1097\/J.PAIN.0000000000002266","journal-title":"Pain"},{"key":"2719_CR39","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3390\/brainsci13020325","volume":"13","author":"A Hasbi","year":"2023","unstructured":"Hasbi A, Madras BK, George SR (2023) Endocannabinoid system and exogenous cannabinoids in depression and anxiety: a review. Brain Sci 13:325. https:\/\/doi.org\/10.3390\/brainsci13020325","journal-title":"Brain Sci"},{"key":"2719_CR40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/mdc3.13414","volume":"9","author":"SK Holden","year":"2022","unstructured":"Holden SK, Domen CH, Sillau S et al (2022) Higher Risk, Higher Reward? Self-Reported effects of real-world cannabis use in Parkinson\u2019s disease. Mov Disord Clin Pract 9:340\u2013350. https:\/\/doi.org\/10.1002\/mdc3.13414","journal-title":"Mov Disord Clin Pract"},{"key":"2719_CR41","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/MDS.20214","volume":"19","author":"HC Jabush","year":"2004","unstructured":"Jabush HC, Schneider U, Altenm\u00fcller E (2004) Delta9-tetrahydrocannabinol improves motor control in a patient with musician\u2019s dystonia. Mov Disord 19:990\u2013991. https:\/\/doi.org\/10.1002\/MDS.20214","journal-title":"Mov Disord"},{"key":"2719_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/brainsci7050047","volume":"7","author":"A Kanaan","year":"2017","unstructured":"Kanaan A, Jakubovski E, M\u00fcller-Vahl K (2017) Significant tic reduction in an otherwise treatment-resistant patient with Gilles de la Tourette Syndrome Following Treatment with Nabiximols. Brain Sci 7:47. https:\/\/doi.org\/10.3390\/brainsci7050047","journal-title":"Brain Sci"},{"key":"2719_CR43","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","volume":"28","author":"T Karl","year":"2017","unstructured":"Karl T, Garner B, Cheng D (2017) The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer\u2019s disease. Behav Pharmacol 28:142\u2013160. https:\/\/doi.org\/10.1097\/FBP.0000000000000247","journal-title":"Behav Pharmacol"},{"key":"2719_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.yebeh.2019.05.037","volume":"97","author":"A Kerr","year":"2019","unstructured":"Kerr A, Walston V, Wong VSS et al (2019) Marijuana use among patients with epilepsy at a tertiary care center. Epilepsy Behav 97:144\u2013148. https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.037","journal-title":"Epilepsy Behav"},{"key":"2719_CR45","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/J.CTIM.2017.07.002","volume":"33","author":"JH Kindred","year":"2017","unstructured":"Kindred JH, Li K, Ketelhut NB et al (2017) Cannabis use in people with Parkinson\u2019s disease and Multiple Sclerosis: A web-based investigation. Complement Ther Med 33:99\u2013104. https:\/\/doi.org\/10.1016\/J.CTIM.2017.07.002","journal-title":"Complement Ther Med"},{"key":"2719_CR46","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/mds.26142","volume":"30","author":"B Kluger","year":"2015","unstructured":"Kluger B, Triolo P, Jones W, Jankovic J (2015) The therapeutic potential of cannabinoids for movement disorders. Mov Disord 30:313\u2013327. https:\/\/doi.org\/10.1002\/mds.26142","journal-title":"Mov Disord"},{"key":"2719_CR47","first-page":"1290","volume":"119","author":"C Kurz","year":"2022","unstructured":"Kurz C, Lau T (2022) Begleiterhebung Zu Medizinischem Cannabis - Bedingt Aussagekr\u00e4ftig 119:1290\u20131291","journal-title":"Begleiterhebung Zu Medizinischem Cannabis - Bedingt Aussagekr\u00e4ftig"},{"key":"2719_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s40263-021-00807-y","volume":"35","author":"S Lattanzi","year":"2021","unstructured":"Lattanzi S, Trinka E, Striano P et al (2021) Highly purified cannabidiol for epilepsy treatment: a systematic review of epileptic conditions beyond Dravet Syndrome and Lennox-Gastaut syndrome. CNS Drugs 35:265\u2013281. https:\/\/doi.org\/10.1007\/s40263-021-00807-y","journal-title":"CNS Drugs"},{"key":"2719_CR49","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1007\/s00415-016-8145-9","volume":"263","author":"JL L\u00f3pez-Send\u00f3n Moreno","year":"2016","unstructured":"L\u00f3pez-Send\u00f3n Moreno JL, Garc\u00eda Caldentey J, Trigo Cubillo P et al (2016) A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington\u2019s disease. J Neurol 263:1390\u20131400. https:\/\/doi.org\/10.1007\/s00415-016-8145-9","journal-title":"J Neurol"},{"key":"2719_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNF.0000000000000016","volume":"37","author":"I Lotan","year":"2014","unstructured":"Lotan I, Treves TA, Roditi Y, Djaldetti R (2014) Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study. Clin Neuropharmacol 37:41\u201344. https:\/\/doi.org\/10.1097\/WNF.0000000000000016","journal-title":"Clin Neuropharmacol"},{"key":"2719_CR51","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2012.0821","author":"AG Ludolph","year":"2012","unstructured":"Ludolph AG, Roessner V, M\u00fcnchau A, M\u00fcller-Vahl K (2012) Tourette Syndrome and Other Tic Disorders in Childhood, Adolescence and Adulthood. Deutsches Aerzteblatt Online. https:\/\/doi.org\/10.3238\/arztebl.2012.0821","journal-title":"Deutsches Aerzteblatt Online."},{"key":"2719_CR52","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s15005-023-3172-4","volume":"25","author":"T Mainka","year":"2023","unstructured":"Mainka T, Buhmann C (2023) Cannabinoide in der Neurologie. InFo Neurologie + Psychiatrie 25:32\u201341. https:\/\/doi.org\/10.1007\/s15005-023-3172-4","journal-title":"InFo Neurologie + Psychiatrie"},{"key":"2719_CR53","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1055\/s-0043-120668","volume":"86","author":"T Mainka","year":"2018","unstructured":"Mainka T, Stork J, Hidding U, Buhmann C (2018) Cannabis in Parkinson\u2019s Disease: Hype or help? Fortschr Neurol Psychiatr 86:106\u2013116. https:\/\/doi.org\/10.1055\/s-0043-120668","journal-title":"Fortschr Neurol Psychiatr"},{"key":"2719_CR54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/S10072-017-3148-6","volume":"39","author":"GT Maniscalco","year":"2018","unstructured":"Maniscalco GT, Aponte R, Bruzzese D et al (2018) THC\/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: a pilot prospective study. Neurol Sci 39:97\u2013102. https:\/\/doi.org\/10.1007\/S10072-017-3148-6","journal-title":"Neurol Sci"},{"key":"2719_CR55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1080\/00207454.2018.1481066","volume":"129","author":"J Markov\u00e0","year":"2019","unstructured":"Markov\u00e0 J, Essner U, Akmaz B et al (2019) Sativex\u00ae as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial. Int J Neurosci 129:119\u2013128. https:\/\/doi.org\/10.1080\/00207454.2018.1481066","journal-title":"Int J Neurosci"},{"key":"2719_CR56","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10072-019-04196-5","volume":"41","author":"MM Mascia","year":"2020","unstructured":"Mascia MM, Carmagnini D, Defazio G (2020) Cannabinoids and dystonia: an issue yet to be defined. Neurol Sci 41:783\u2013787. https:\/\/doi.org\/10.1007\/s10072-019-04196-5","journal-title":"Neurol Sci"},{"key":"2719_CR57","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/CAN.2018.0050","volume":"4","author":"LM Milosev","year":"2019","unstructured":"Milosev LM, Psathakis N, Szejko N et al (2019) Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine: Results from a Retrospective Analysis and Online Survey. Cannabis Cannabinoid Res 4:265\u2013274. https:\/\/doi.org\/10.1089\/CAN.2018.0050","journal-title":"Cannabis Cannabinoid Res"},{"key":"2719_CR58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12906-019-2803-2","volume":"20","author":"N Montero-Oleas","year":"2020","unstructured":"Montero-Oleas N, Arevalo-Rodriguez I, Nu\u00f1ez-Gonz\u00e1lez S et al (2020) Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews. BMC Complement Med Ther 20:12. https:\/\/doi.org\/10.1186\/s12906-019-2803-2","journal-title":"BMC Complement Med Ther"},{"key":"2719_CR59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012182.pub2","volume":"3","author":"M M\u00fccke","year":"2018","unstructured":"M\u00fccke M, Phillips T, Radbruch L et al (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev 3:CD012182. https:\/\/doi.org\/10.1002\/14651858.CD012182.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"2719_CR60","doi-asserted-by":"publisher","unstructured":"Mueller RL, Ellingson JM, Bidwell LC, et al (2021) Are the Acute Effects of THC Different in Aging Adults? https:\/\/doi.org\/10.3390\/brainsci11050590","DOI":"10.3390\/brainsci11050590"},{"key":"2719_CR61","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.neuro.2022.09.001","volume":"93","author":"F Muhammad","year":"2022","unstructured":"Muhammad F, Liu Y, Wang N et al (2022) Neuroprotective effects of cannabidiol on dopaminergic neurodegeneration and \u03b1-synuclein accumulation in C. elegans models of Parkinson\u2019s disease. Neurotoxicology 93:128\u2013139. https:\/\/doi.org\/10.1016\/j.neuro.2022.09.001","journal-title":"Neurotoxicology"},{"key":"2719_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/BEN-120276","volume":"27","author":"KR M\u00fcller-Vahl","year":"2013","unstructured":"M\u00fcller-Vahl KR (2013) Treatment of Tourette syndrome with cannabinoids. Behav Neurol 27:119\u2013124. https:\/\/doi.org\/10.3233\/BEN-120276","journal-title":"Behav Neurol"},{"key":"2719_CR63","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1055\/S-2002-25028","volume":"156","author":"KR M\u00fcller-Vahl","year":"1999","unstructured":"M\u00fcller-Vahl KR, Schneider U, Kolbe H, Emrich HM (1999) Treatment of Tourette\u2019s syndrome with delta-9-tetrahydrocannabinol. Am J Psychiatry 156:495. https:\/\/doi.org\/10.1055\/S-2002-25028","journal-title":"Am J Psychiatry"},{"key":"2719_CR64","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1055\/S-2002-25028","volume":"35","author":"KR M\u00fcller-Vahl","year":"2002","unstructured":"M\u00fcller-Vahl KR, Schneider U, Koblenz A et al (2002) Treatment of Tourette\u2019s syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry 35:57\u201361. https:\/\/doi.org\/10.1055\/S-2002-25028","journal-title":"Pharmacopsychiatry"},{"key":"2719_CR65","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.V64N0417","volume":"64","author":"KR M\u00fcller-Vahl","year":"2003","unstructured":"M\u00fcller-Vahl KR, Schneider U, Prevedel H et al (2003) Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J Clin Psychiatry 64:459\u2013465. https:\/\/doi.org\/10.4088\/JCP.V64N0417","journal-title":"J Clin Psychiatry"},{"key":"2719_CR66","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1002\/MDS.28681","volume":"36","author":"KR M\u00fcller-Vahl","year":"2021","unstructured":"M\u00fcller-Vahl KR, Fremer C, Beals C et al (2021) Monoacylglycerol lipase inhibition in Tourette syndrome: a 12-week, randomized, controlled study. Mov Disord 36:2413\u20132418. https:\/\/doi.org\/10.1002\/MDS.28681","journal-title":"Mov Disord"},{"key":"2719_CR67","doi-asserted-by":"publisher","DOI":"10.1007\/S11910-018-0814-X","author":"S Nielsen","year":"2018","unstructured":"Nielsen S, Germanos R, Weier M et al (2018) The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. https:\/\/doi.org\/10.1007\/S11910-018-0814-X","journal-title":"Curr Neurol Neurosci Rep"},{"key":"2719_CR68","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1124\/jpet.109.158162","volume":"331","author":"B Pan","year":"2009","unstructured":"Pan B, Wang W, Long JZ et al (2009) Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther 331:591\u2013597. https:\/\/doi.org\/10.1124\/jpet.109.158162","journal-title":"J Pharmacol Exp Ther"},{"key":"2719_CR69","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ncl.2020.09.012","volume":"39","author":"AD Patel","year":"2021","unstructured":"Patel AD (2021) Cannabinoids in Neurologic Illnesses. Neurol Clin 39:231\u2013241. https:\/\/doi.org\/10.1016\/j.ncl.2020.09.012","journal-title":"Neurol Clin"},{"key":"2719_CR70","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/S00702-019-02021-Z","volume":"126","author":"M Peball","year":"2019","unstructured":"Peball M, Werkmann M, Ellmerer P et al (2019) Nabilone for non-motor symptoms of Parkinson\u2019s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). J Neural Transm (vienna) 126:1061\u20131072. https:\/\/doi.org\/10.1007\/S00702-019-02021-Z","journal-title":"J Neural Transm (vienna)"},{"key":"2719_CR71","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ana.25864","volume":"88","author":"M Peball","year":"2020","unstructured":"Peball M, Krismer F, Knaus H et al (2020) Non-Motor Symptoms in Parkinson\u2019s Disease are Reduced by Nabilone. Ann Neurol 88:712\u2013722. https:\/\/doi.org\/10.1002\/ana.25864","journal-title":"Ann Neurol"},{"key":"2719_CR72","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/MDC3.13471","volume":"9","author":"M Peball","year":"2022","unstructured":"Peball M, Seppi K, Krismer F et al (2022) Effects of Nabilone on sleep outcomes in patients with Parkinson\u2019s disease: a post-hoc analysis of NMS-Nab Study. Mov Disord Clin Pract 9:751\u2013758. https:\/\/doi.org\/10.1002\/MDC3.13471","journal-title":"Mov Disord Clin Pract"},{"key":"2719_CR73","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.tips.2016.12.002","volume":"38","author":"S Pisanti","year":"2017","unstructured":"Pisanti S, Bifulco M (2017) Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back. Trends Pharmacol Sci 38:195\u2013198. https:\/\/doi.org\/10.1016\/j.tips.2016.12.002","journal-title":"Trends Pharmacol Sci"},{"key":"2719_CR74","unstructured":"Potschka H, Brandl U (2017) Stellungnahme zu Cannabis (und extrahierter Wirkstoffe) in der Epilepsiebehandlung"},{"key":"2719_CR75","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.17407","author":"S Poudel","year":"2021","unstructured":"Poudel S, Quinonez J, Choudhari J et al (2021) Medical Cannabis, headaches, and migraines: a review of the current literature. Cureus. https:\/\/doi.org\/10.7759\/cureus.17407","journal-title":"Cureus"},{"key":"2719_CR76","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/01658107.2017.1318150","volume":"41","author":"PM Radke","year":"2017","unstructured":"Radke PM, Mokhtarzadeh A, Lee MS, Harrison AR (2017) Medical Cannabis, a beneficial high in treatment of blepharospasm? An early observation. Neuroophthalmology 41:253\u2013258. https:\/\/doi.org\/10.1080\/01658107.2017.1318150","journal-title":"Neuroophthalmology"},{"key":"2719_CR77","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1474-4422(18)30406-X","volume":"18","author":"N Riva","year":"2019","unstructured":"Riva N, Mora G, Sorar\u00f9 G et al (2019) Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol 18:155\u2013164. https:\/\/doi.org\/10.1016\/S1474-4422(18)30406-X","journal-title":"Lancet Neurol"},{"key":"2719_CR78","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/S00787-021-01899-Z","volume":"31","author":"V Roessner","year":"2022","unstructured":"Roessner V, Eichele H, Stern JS et al (2022) European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment. Eur Child Adolesc Psychiatry 31:425\u2013441. https:\/\/doi.org\/10.1007\/S00787-021-01899-Z","journal-title":"Eur Child Adolesc Psychiatry"},{"key":"2719_CR79","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1093\/PM\/PNV080","volume":"17","author":"M Russo","year":"2016","unstructured":"Russo M, Naro A, Leo A et al (2016) Evaluating Sativex\u00ae in neuropathic pain management: a clinical and neurophysiological assessment in multiple sclerosis. Pain Med 17:1145\u20131154. https:\/\/doi.org\/10.1093\/PM\/PNV080","journal-title":"Pain Med"},{"key":"2719_CR80","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3233\/JHD-170283","volume":"7","author":"C Saft","year":"2018","unstructured":"Saft C, von Hein SM, L\u00fccke T et al (2018) Cannabinoids for treatment of dystonia in Huntington\u2019s Disease. J Huntingtons Dis 7:167\u2013173. https:\/\/doi.org\/10.3233\/JHD-170283","journal-title":"J Huntingtons Dis"},{"key":"2719_CR81","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/jnr.22682","volume":"89","author":"O Sagredo","year":"2011","unstructured":"Sagredo O, Pazos MR, Satta V et al (2011) Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington\u2019s disease. J Neurosci Res 89:1509\u20131518. https:\/\/doi.org\/10.1002\/jnr.22682","journal-title":"J Neurosci Res"},{"key":"2719_CR82","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/00004714-198812000-00021","volume":"8","author":"R Sandyk","year":"1988","unstructured":"Sandyk R, Awerbuch G (1988) Marijuana and Tourette\u2019s syndrome. J Clin Psychopharmacol 8:444\u2013445. https:\/\/doi.org\/10.1097\/00004714-198812000-00021","journal-title":"J Clin Psychopharmacol"},{"key":"2719_CR83","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/0165-1781(86)90117-4","volume":"18","author":"R Sandyk","year":"1986","unstructured":"Sandyk R, Snider SR, Consroe P, Elias SM (1986) Cannabidiol in dystonic movement disorders. Psychiatry Res 18:291. https:\/\/doi.org\/10.1016\/0165-1781(86)90117-4","journal-title":"Psychiatry Res"},{"key":"2719_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103638","volume":"59","author":"TM Santarossa","year":"2022","unstructured":"Santarossa TM, So R, Smyth DP et al (2022) Medical cannabis use in Canadians with multiple sclerosis. Mult Scler Relat Disord 59:103638. https:\/\/doi.org\/10.1016\/j.msard.2022.103638","journal-title":"Mult Scler Relat Disord"},{"key":"2719_CR85","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","volume":"57","author":"KA Sieradzan","year":"2001","unstructured":"Sieradzan KA, Fox SH, Hill M et al (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57:2108\u20132111. https:\/\/doi.org\/10.1212\/WNL.57.11.2108","journal-title":"Neurology"},{"key":"2719_CR86","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/ene.13623","volume":"25","author":"M Sorosina","year":"2018","unstructured":"Sorosina M, Clarelli F, Ferr\u00e8 L et al (2018) Clinical response to Nabiximols correlates with the downregulation of immune pathways in multiple sclerosis. Eur J Neurol 25:934-e70. https:\/\/doi.org\/10.1111\/ene.13623","journal-title":"Eur J Neurol"},{"key":"2719_CR87","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1136\/JNNP-2017-317168","volume":"89","author":"E Stockings","year":"2018","unstructured":"Stockings E, Zagic D, Campbell G et al (2018) Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence. J Neurol Neurosurg Psychiatry 89:741\u2013753. https:\/\/doi.org\/10.1136\/JNNP-2017-317168","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2719_CR88","doi-asserted-by":"publisher","first-page":"176","DOI":"10.2174\/1570159X16666180702144644","volume":"17","author":"G Talarico","year":"2019","unstructured":"Talarico G, Trebbastoni A, Bruno G, de Lena C (2019) Modulation of the cannabinoid system: a new perspective for the treatment of the Alzheimer\u2019s disease. Curr Neuropharmacol 17:176\u2013183. https:\/\/doi.org\/10.2174\/1570159X16666180702144644","journal-title":"Curr Neuropharmacol"},{"key":"2719_CR89","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211018561","author":"SJ Thanabalasingam","year":"2021","unstructured":"Thanabalasingam SJ, Ranjith B, Jackson R, Wijeratne DT (2021) Cannabis and its derivatives for the use of motor symptoms in Parkinson\u2019s disease: a systematic review and meta-analysis. Ther Adv Neurol Disord. https:\/\/doi.org\/10.1177\/17562864211018561","journal-title":"Ther Adv Neurol Disord"},{"key":"2719_CR90","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","volume":"391","author":"EA Thiele","year":"2018","unstructured":"Thiele EA, Marsh ED, French JA et al (2018) Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391:1085\u20131096. https:\/\/doi.org\/10.1016\/S0140-6736(18)30136-3","journal-title":"Lancet"},{"key":"2719_CR91","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1001\/JAMANEUROL.2020.4607","volume":"78","author":"EA Thiele","year":"2021","unstructured":"Thiele EA, Bebin EM, Bhathal H et al (2021) Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial. JAMA Neurol 78:285\u2013292. https:\/\/doi.org\/10.1001\/JAMANEUROL.2020.4607","journal-title":"JAMA Neurol"},{"key":"2719_CR92","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/EPI.17150","volume":"63","author":"EA Thiele","year":"2022","unstructured":"Thiele EA, Bebin EM, Filloux F et al (2022) Long-term cannabidiol treatment for seizures in patients with tuberous sclerosis complex: an open-label extension trial. Epilepsia 63:426\u2013439. https:\/\/doi.org\/10.1111\/EPI.17150","journal-title":"Epilepsia"},{"key":"2719_CR93","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2018.3485","volume":"1","author":"MC Torres-Moreno","year":"2018","unstructured":"Torres-Moreno MC, Papaseit E, Torrens M, Farr\u00e9 M (2018) Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis. JAMA Netw Open 1:e183485. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2018.3485","journal-title":"JAMA Netw Open"},{"key":"2719_CR94","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1177\/1039856216663737","volume":"24","author":"D Trainor","year":"2016","unstructured":"Trainor D, Evans L, Bird R (2016) Severe motor and vocal tics controlled with Sativex \u00ae. Australas Psychiatry 24:541\u2013544. https:\/\/doi.org\/10.1177\/1039856216663737","journal-title":"Australas Psychiatry"},{"key":"2719_CR95","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2019-029449","author":"B Urbi","year":"2019","unstructured":"Urbi B, Broadley S, Bedlack R et al (2019) Study protocol for a randomised, double-blind, placebo-controlled study evaluating the efficacy of cannabis-based Medicine Extract in slowing the disease pRogression of Amyotrophic Lateral sclerosis or motor neurone Disease: the EMERALD trial. BMJ Open. https:\/\/doi.org\/10.1136\/BMJOPEN-2019-029449","journal-title":"BMJ Open"},{"key":"2719_CR96","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3233\/JPD-212923","volume":"12","author":"B Urbi","year":"2022","unstructured":"Urbi B, Corbett J, Hughes I et al (2022) Effects of cannabis in Parkinson\u2019s disease: a systematic review and meta-analysis. J Parkinsons Dis 12:495\u2013508. https:\/\/doi.org\/10.3233\/JPD-212923","journal-title":"J Parkinsons Dis"},{"key":"2719_CR97","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1021\/CN200114W","volume":"3","author":"S Valdeolivas","year":"2012","unstructured":"Valdeolivas S, Satta V, Pertwee RG et al (2012) Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington\u2019s disease: role of CB1 and CB2 receptors. ACS Chem Neurosci 3:400\u2013406. https:\/\/doi.org\/10.1021\/CN200114W","journal-title":"ACS Chem Neurosci"},{"key":"2719_CR98","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/ijms18040684","volume":"18","author":"S Valdeolivas","year":"2017","unstructured":"Valdeolivas S, Sagredo O, Delgado M et al (2017) Effects of a Sativex-Like combination of phytocannabinoids on disease progression in R6\/2 mice, an experimental model of Huntington\u2019s Disease. Int J Mol Sci 18:684. https:\/\/doi.org\/10.3390\/ijms18040684","journal-title":"Int J Mol Sci"},{"key":"2719_CR99","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1002\/mds.20111","volume":"19","author":"K Venderov\u00e1","year":"2004","unstructured":"Venderov\u00e1 K, R\u016fzicka E, Vor\u00edsek V, Visnovsk\u00fd P (2004) Survey on cannabis use in Parkinson\u2019s disease: subjective improvement of motor symptoms. Mov Disord 19:1102\u20131106. https:\/\/doi.org\/10.1002\/mds.20111","journal-title":"Mov Disord"},{"key":"2719_CR100","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","volume":"12","author":"L Volicer","year":"1997","unstructured":"Volicer L, Stelly M, Morris J et al (1997) Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease. Int J Geriatr Psychiatry 12:913\u2013919. https:\/\/doi.org\/10.1002\/(SICI)1099-1166(199709)12:9%3c913::AID-GPS663%3e3.0.CO;2-D","journal-title":"Int J Geriatr Psychiatry"},{"key":"2719_CR101","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1177\/1352458510367462","volume":"16","author":"DT Wade","year":"2010","unstructured":"Wade DT, Collin C, Stott C, Duncombe P (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler J 16:707\u2013714. https:\/\/doi.org\/10.1177\/1352458510367462","journal-title":"Mult Scler J"},{"key":"2719_CR102","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","volume":"185","author":"S Walther","year":"2006","unstructured":"Walther S, Mahlberg R, Eichmann U, Kunz D (2006) Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology 185:524\u2013528. https:\/\/doi.org\/10.1007\/s00213-006-0343-1","journal-title":"Psychopharmacology"},{"key":"2719_CR103","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/JNNP.2009.200642","volume":"81","author":"M Weber","year":"2010","unstructured":"Weber M, Goldman B, Truniger S (2010) Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry 81:1135\u20131140. https:\/\/doi.org\/10.1136\/JNNP.2009.200642","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2719_CR104","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3233\/JPD-202260","volume":"11","author":"F Yenilmez","year":"2021","unstructured":"Yenilmez F, Fr\u00fcndt O, Hidding U, Buhmann C (2021) Cannabis in Parkinson\u2019s disease: the patients\u2019 view. J Parkinsons Dis 11:309\u2013321. https:\/\/doi.org\/10.3233\/JPD-202260","journal-title":"J Parkinsons Dis"},{"key":"2719_CR105","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/J.BAGA.2011.04.002","volume":"1","author":"C Zadikoff","year":"2011","unstructured":"Zadikoff C, Wadia PM, Miyasaki J et al (2011) Cannabinoid, CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled trial. Basal Ganglia 1:91\u201395. https:\/\/doi.org\/10.1016\/J.BAGA.2011.04.002","journal-title":"Basal Ganglia"},{"key":"2719_CR106","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/S00417-021-05533-1","volume":"260","author":"O Zloto","year":"2022","unstructured":"Zloto O, Weisman A, Avisar I et al (2022) Medical cannabis oil for benign essential blepharospasm: a prospective, randomized controlled pilot study. Graefes Arch Clin Exp Ophthalmol 260:1707\u20131712. https:\/\/doi.org\/10.1007\/S00417-021-05533-1","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2719_CR107","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JAS, Hallak JEC et al (2009) Cannabidiol for the treatment of psychosis in Parkinson\u2019s disease. J Psychopharmacol 23:979\u2013983. https:\/\/doi.org\/10.1177\/0269881108096519","journal-title":"J Psychopharmacol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02719-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-023-02719-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-023-02719-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T10:12:43Z","timestamp":1705399963000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-023-02719-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2719"],"URL":"https:\/\/doi.org\/10.1007\/s00702-023-02719-1","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]},"assertion":[{"value":"10 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they were not guided by any economic interests when creating the article. TM is supported by the BIH-Charit\u00e9 Clinician Scientist Program of the Charit\u00e9-Universit\u00e4tsmedizin Berlin and the Berlin Institute of Health. She has received author fees from Elsevier and Urban & Fischer, lecture fees from Stadapharm and BIAL and has served on the Advisory Board of Biomarin Pharmaceutical. CB has received author fees from Kohlhammer, Springer and Thieme, advisory board fees from Stadapharm and Zambon, and speaking honoraria from AbbVie, Abbott, BIAL, Hormosan, and Zambon.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}